Prediabetes, diabetes prevention, and obesity

Using liraglutide in people with obesity and prediabetes is a valuable strategy for weight loss, but improvements are greater with caloric restriction alone, suggest study results.

A randomized trial demonstrates significant reductions in visceral adipose tissue in people with obesity but without diabetes taking the glucagon-like peptide-1 receptor agonist liraglutide.

Divergent changes in brain activity after bariatric surgery versus a very-low-calorie diet may help explain why people are more likely to regain weight after the latter intervention, a study suggests.

Taking semaglutide 2.4 mg can reduce the likelihood of people with overweight or obesity developing type 2 diabetes, shows further analysis of STEP 1.

A study shows marked variations in cardiovascular risk burden according to age, sex, and ethnicity at the point of type 2 diabetes diagnosis, with implications for both diabetes prevention and cardiovascular risk management.

Liraglutide 3.0 mg boosts weight loss in obese adolescents receiving lifestyle therapy, show the findings of a phase 3 trial.

Severely obese people show evidence of impaired cognition even when they have no signs of prediabetes or diabetes, but retinopathy and nephropathy only occur in those with hyperglycemia, US research shows.

Restricting eating to within a 10-hour daily window results in weight loss and metabolic benefits for people with metabolic syndrome, report researchers in Cell Metabolism.

People who are trying to maintain weight loss with the help of electronic health records-based tracking tools do significantly better if they are given access to an online coach, shows a randomized trial.

Obese adults with prediabetes may need a longer-than-recommended course of behavioral weight loss treatment to optimize improvements in glycemic control, US researchers report.

Fifteen years of follow-up of the DPP trial shows that although people initially lost more weight with the intensive lifestyle intervention, those assigned to metformin did better at keeping the weight off in the long term.

The rate at which BMI changes throughout childhood and adolescence is significantly associated with adult hyperglycemia, independent of BMI level at specific time points, study findings indicate.

The results of the adult surgery study from the RISE consortium show that gastric banding has only a small effect on the deterioration of beta-cell function relative to metformin, despite causing markedly greater weight loss.

The RISE investigators have reported a continued lack of effect of early intensive therapy on beta-cell function decline in children with prediabetes or early type 2 diabetes.

The PREVIEW project investigators have reported broadly positive results, but tempered by issues such as a high dropout rate.

Losing weight in the CAMELLIA-TIMI 61 trial was associated with a significantly reduced risk for developing type 2 diabetes, the investigators have reported at the 54th EASD Annual Meeting in Berlin, Germany.

Impaired glucose tolerance in obese youths frequently reverts to normal, although the chances of this happening are strongly influenced by ethnicity, researchers report in The Lancet Child & Adolescent Health.

Adding body fat percentage to BMI improves the classification of individuals at risk for abnormal blood glucose, US researchers report.

The latest update from the NHS Diabetes Prevention Programme shows that more people than expected are engaging with the scheme.

Objectively measured physical activity is associated with a reduction in cardiometabolic risk markers among people with prediabetes, and the total time spent being active is at least as important as exercise intensity, researchers report.